Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 25: Short-Term Anticoagulation Vs DAPT for Preventing Device Thrombosis Following LAAC
Author(s): Josep Rodés-Cabau Added: 3 weeks ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device… View more

Anticoagulation

Imaging & Diagnostics
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 4 days ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

Heart Failure

Prevention & Chronic Conditions
The Future of Heart Failure With Dr Yancy
Author(s): Clyde W Yancy Added: 19 hours ago
AHA 2025 - Dr Clyde Yancy (Northwestern University, US) joins us to explore the future trajectory of heart failure management, examining how prevention strategies, precision medicine approaches, and the evolving responsibilities of cardiologists are reshaping patient outcomes.Interview Questions:Looking at the current state of heart failure management, what do you see as the most significant… View more

Guidelines & Statements

Heart Failure
Prevention: What's New at HFA 2025?
Author(s): Harriette Van Spall , Maja Cikes Added: 6 months ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE… View more

Heart Failure
Clinical Clues in Cardiovascular Disease
Author(s): Yassir Javaid , Faizel Osman , Renate B Schnabel , et al Added: 2 months ago
This six-part interview series, recorded around ESC 2025, brings together leading experts to share strategies for earlier and more accurate detection of cardiovascular disease. The discussions highlight how atypical or subtle symptoms of stroke and heart failure can delay diagnosis, and why vigilance in routine practice is critical.The series also examines sex-specific differences in cardiac… View more

CV Disease in Special Populations

Electrophysiology & Arrhythmia
Selecting NOAC to Optimise Stroke Prevention in AF – Part 1
Author(s): Tri Huynh Quang Ho , Minh That Ton , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 1 year ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Guidelines & Statements

Prevention & Chronic Conditions
Selecting NOAC to Optimise Stroke Prevention in AF – Part 2
Author(s): Minh That Ton , Tri Huynh Quang Ho , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 8 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 2 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery